Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
MINNEAPOLIS, Feb. 02, 2016 -- Urologix, Inc. (OTC Pink:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today that as of the close of business on January 29, 2015 substantially all of the operating assets of Urologix, Inc. including the Urologix name were surrendered to a secured creditor and subsequently purchased by a private company to partially address the secured debt owed to the secured creditor. The sale of Urologix’s operating assets was contemplated by a forbearance agreement entered into with the secured creditor on December 7, 2015. The buyer will operate the existing business through an entity named “Urologix, LLC.”
The transaction will enable Urologix, LLC to provide urology customers and their patients with both Cooled ThermoTherapy and Prostiva RF Therapy products and services to treat BPH in the comfortable setting of a urologist’s office.
Concurrent with these events, Urologix, Inc. was renamed 21st North Inc. Immediately following the transaction, 21st North Inc. has no operations and has commenced an orderly wind down. Accordingly, 21st North intends to submit a proposal to its shareholders in the ensuing weeks to approve a plan of dissolution. The Company will not be making liquidating distributions to shareholders at any time.
Contact Information: Greg Fluet [email protected]
